Innovating solutions for accessible recovery
Frenelle PBC values equal access and putting patients first. We strive to improve the patient experience, and ensure critical medications are accessible to all.
Opioid Use Disorder
Opioid misuse affects 10 million individuals in the U.S., with 2.7 million formally diagnosed with Opioid Use Disorder (OUD) and 1.8 million treated with buprenorphine.
Many OUD patients relapse, supporting the need for an improved long-acting injectable treatment to enable patients to break this cycle.
Frenelle PBC values equal access and putting patients first. We strive to improve the patient experience, and ensure critical medications are accessible to all.
Opioid Use Disorder
Opioid misuse affects 10 million individuals in the U.S., with 2.7 million formally diagnosed with Opioid Use Disorder (OUD) and 1.8 million treated with buprenorphine.
Many OUD patients relapse, supporting the need for an improved long-acting injectable treatment to enable patients to break this cycle.
Frenelle PBC has partnered with the Mayo Clinic to leverage Frenelle’s Faros™ technology and Mayo Clinic’s addiction medicine expertise to create effective and accessible treatment options for patients and loved ones suffering from substance use disorders.
Our innovative approach aims to provide a 30-day subcutaneous injection of buprenorphine (FRN03), delivering sustained OUD maintenance therapy with reduced injection site pain and without the serious safety risks associated with the current long-acting products.
Pre-clinical
IND-enabling
Ph1
Ph2
FRN03
awdawd_edited.jpg)
Frenelle PBC has partnered with the Mayo Clinic to leverage Frenelle’s Faros™ technology and Mayo Clinic’s addiction medicine expertise to create effective and accessible treatment options for patients and loved ones suffering from substance use disorders.
Our innovative approach aims to provide a 30-day subcutaneous injection of buprenorphine (FRN03), delivering sustained OUD maintenance therapy with reduced injection site pain and without the serious safety risks associated with the current long-acting products.
Pre-clinical
IND-enabling
Ph1
Ph2
FRN03
Pipeline
.jpg)